Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07067268
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
A Multicenter, Randomized Controlled, Phase II Trail of Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA After Radiotherapy
Sponsor: Fudan University
Conditions
Nasopharyngeal Cancinoma (NPC)
Interventions
Adjuvant therapy
Updated 1 time since 2025 Last updated: Jul 5, 2025 Started: Sep 14, 2024 Primary completion: Sep 30, 2026 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Nasopharyngeal Cancinoma (NPC) and is currently actively recruiting participants. Fudan University leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fudan University
Data source: Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .